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ABSTRACT: Af/oreacti~De T ctlLr generated as clones/rom lnixtd lyrnphocyte (1IIIUrtS, or propagated/rom 
heart or liver Irallsplanl biopsies, were lested /01' srrond(lry proliferation "Itrmmd in the primed 
lymphocyte ItSI in the prewICe of Cyclosporint A arid tnt/abo/iltS /l'lIrtioTlIIJed from h,mlan bik 
Significant dilfermees I/lm olmrtled i71 Cydo1porine /\ 1",sil;/lily between various ctli CIt/tllrtS 
rllnging as high as 100-lold. The liver is the primary sile of Cyd(uporine A metabolism, whirh 
yields II nllmber of hydroxy/attd ana N-di1/ltlhylg/td dtrivativts that an t1)t1Itllally secreled into 
the bile. Bile was col/«ud from 4111111 Ih'er tramp/ani patients on Cydosporine A therapy and 
following ext rae/ion with dit/hy/ ether. separllua by high pmum liquid chrolllflfography. Thir-
Jeen /rartiom were leJttd for their efficl on Iyl1lphocylt proliferation in concanavalin A acliva/ion, 
mixed Iymphocylt m!tlirts and primed lymphocyte fest IISsays. The Jlrrmgest immlmoIflppress;/ie 
ef/ect was follnd with fraction 8. which contaimd metabolitt MI7. which has a single hyartJxyl-
alion in position 1. Ollly thm other fractions 9, 10, alJd 13, which cOlltaimd metabolites MI, 
M 18, alld M21 • respecfively, txhibited itllll11tnoSllpprfSJive activity. alb,illl1lJch lower Ihan thaI 
0/ Cyc/osporim A. DiffmllceI in Cyclosporitle A sensitivity among alioreacJitle T rells followed 
similar patterns with Cyclosporine A metabolites. Thll1. the asmsrnmt of the Cye/offtorinl A 
effect mllsJ consider dif/mnCtS ill drtlg s",sil1vity ollymphocyltS im'olvtd ill transp/alll immllnity 
alld the gmeration of metaboliles with imnlllnrJJlIppnrsive arJivity. 
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Although cyclosporine A (CsA) has a powerful immunosuppressive effect on 
allograft rejection, many transplant recipients experience rejection episodes (hat 
are often irreversible. Rejection is generally mediated by activated T cells infil-
crating the allograft. Recenrly developed methodologies of propagating activated 
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FIGURE 1 Schematical diagram of the pathways of Cyclosporine A metaboli~mK 
T cells from transplanted tissues have demonstrated the presence of donor-
specific lymphocytes in transplanted organs at various stages of rejection [1-3]. 
Donor-specific T cells have also been grown from transplant biopsies without any 
evidence of an ongoing or pending rejection episode as diagnosed clinically or 
histologically [4}. Therefore, the presence of donor-specific alloreactive T lym-
phocytes in allografts may not be always associated with a rejection episode. 
Although absence of rejection might be explained by the presence of suppressor 
cells in the cellular infiltrates, it is also possible that differences in the sensitivity 
of graft-infiltrating lymphocytes to CsA may playa role. Several investigators 
have reported differences among individuals in CsA sensitivity of peripheral 
blood lymphocytes (PBL) activated by mitogen! or in mixed lymphocyte culmre 
(MLC) [5,6]. 
From a practical standpoint, studies of CsA sensitivity of lymphocytes should 
also consider the metabolites of CsA. Structurally, CsA is a cyclic undecapeptide 
with several N-methylated amino acids and a unique unsaturated amino acid. 
Following administration, CsA is metabolized by hydroxylation and N-demethyl-
ation through the mono-oxygenase cytochrome P450 system primarily in [he 
liver (Figure 1) [7]. The CsA metabolites are excreted into the bile and eventu-
ally eliminated through the intestinal tract [8]. 
Several CsA metabolites exhibit immunosuppressive activity as shown by in 
vitro assays with lymphocytes stimulated by mitogens such as phytOhemag-
glutinin (PHA) and concanavalin A (Con A) or in mixed leukocyte reaction 
culture (MLR) [9,10]. Certain metabolites may also inhibit interleukin-2 OL-2l 
production in MLC and the generation of cytotoxic T cells (10J. Particularly. 
metabolites M17 and M1 with single hydroxylations of amino acids in positions I 
.' 
-
~ 
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and 9, respectively, exhibit a considerable degree of immunosuppressive activity, 
which, depending on the type of in vicro assay used, approaches thac ofCsA [10). 
On the other hand, metabolite MS, which is hydroxylated at both amino acids 1 
and 9, as well as metabolite M21, which is N-methylated at amino acid in position 
4, exhibit markedly reduced in vitro immunosuppressive activity [10]. 
The chromatographic fractionation of esA metabolites in human bile from 
liver transplant recipients has been previously reported [II}. Several fractions, 
obtained by high pressure liquid chromatOgraphy (HPLC) have now been tested 
for immunosuppressive effects on in vitro proliferative responses of activated T 
cells. This paper also describes studies showing differences in CsA sensitivity of 
HLA-specific alloreacrive T-cell clones generated from the MLR cultures and 
T-celJ lines propagated from transplant biopsies. 
MATERIALS AND METHODS 
Isolation and Separation of Cyclosporine A Metabolites 
from Human Bile 
Metabolites of CsA were obtained according to previously described methods 
[II}. Briefly, bile was collected from the T-tubes of adult patients who had 
undergone orthotopic liver transplantadon and were receiving CsA therapy. A 
fresh 50-ml bile aliquot was extracted with ethyl ether in a separatory funnel, and 
the ether was removed by evaporation under reduced pressure. The residue was 
taken up in aqueous methanol, washed twice with hexane, and evaporated to 
dryness. Multiple portions of the extract were injected onto an HPLC column 
(octadecylsilane, 5 p.m, 15 em) maintained ac 70°e. The mobile phase was a 
gradient of acetonitrile: water that was varied over 118 min co provide the opti-
mal separation of the component peaks. The column eluent was monitored by 
ultraviolet detection at 214 nm. Each of the major fractions was collected as it 
eluted from the column, was taken co dryness, and was combined with identical 
fractions from other HPLC injections. Purified samples of metabolites Ml, MI7, 
M18, and M21, kindly provided by G. Maurer (Sandoz, Basel, Switzerland) were 
used as standards to verify identical fractions of the eluate. 
Thirteen major fracrions were collected (see Figure 2). Fractions 8,9. 10, and 
FIGURE 2 Chromatogram of an HPLC injection of II. bile extract. Absorbance at 214 
nm over 118 min is shown, wirh the identification of each of the 13 fractions collected. 
Peaks with identical retention times eo M17, MI, MI8, and M21 are identified. The CsA 
was eluted after fraction 13, and the peak is noe shown in rhis figure. 
L.II 
t> 
2 
<I 
al 
ex: 
0 
<II 
CD 
<! 
I-
IX 
!! 
'" 
4 56 7 8 9 10 II 12 13 
(MI7)tMO(MI81 (III21) 
FRACTION NUMBER 
• 
. . ~K~ 
146 Zeevi et al. 
13 had identical retention times with the purified MI7, MI, MI8, and M21, and 
this was further confirmed by mass spectral analysis. Further HPLC analysis 
demonstrated that the bile-derived MI, MI8, and M21 fractions were >95% 
pure, whereas the bile-derived. MI7 fraction contained approximately 10% of 
unidentified material as determlDed from peak area. 
Control bile was collected from pretransplanc cirrhotic patients. The separa-
tion procedure was identical to the above prot~col of separation o~ bile obtained 
from patients on CsA treatment. FractlOns obtalOed from control bIle were tested 
for theif effect on lymphocyte proliferation. 
Lymphocyte Proliferation Assays 
Con A-induced activation. Human PBL were isolated from heparinized blood by 
Ficoll-Hypaque density gradient centrifugation. Using 96-well round-bottomed 
microplates, these cells E1M~/wellF were incubated at 3rC in 200 p.l of tissue 
culture medium (TCM) supplemented with lO% human serum in the presence of 
Can A (10 p.g/ml) for 72 h. During the final 20 h of incubation, each culture was 
labeled with I /LCi of [3HJthymidine. The cultures were harvested and counted 
in liquid scintillation counter as previously described [12]. 
Mixed lymphocyte culture-induced activation. Unidirectional human MLR cultures 
were set up with 10' responder and 10' irradiated (2000 R) stimulator cells in a 
volume of 200 /LI TCM supplemented with 10% human serum for 6 days. Prolif-
eration was assessed by the degree of [3HJthymidine incorporation during the 
final 20 h of incubation [I2}. 1 
Primed lympho'Y1e test testing of alloreacJive T cel/s. Alloreactive human T-cell 
clones were generated from in vitro MLR cultures as previously described [12]. 
Alloreactive lymphocyte cultures were also propagated from human heart and 
liver core biopsies in the presence of IL-2 as previously reported (2,3]. Second-
ary proliferation of alloreaccive cells was assessed in a 3-day primed lymphocyte 
test (PLT), whereby 104 responder cells were incubated with 101 irradiated (2000 
R) stimulator cells [12]. Lymphocyte proliferation was assessed by [-IHJthymi-
dine incorporation as described above. 
Dose Effects of Cyc1osporine A and its Metabolites 
on Lymphocyte Proliferation 
The inhibitory effects of CsA and its 13 bile-derived metabolite fractions on Coo 
A and M~ reactivity and m~q response of alloreactive lymphOCytes were mea-
sured at d1fferent concentratIons of drugs ranging from .005 to 5 p.g/ml. The 
results were expressed as a percentage inhibition using the formula: 
Percentage inhibition = (1 _ cpm ~ith drug ) x 
cpm WIthout drug 100. 
RESULTS 
Dose Effect of Cyclosporine A on Secondary Proliferation of Alloreactive 
T·Cel! Clones 
Four class II an? :wo class I HLA specific alloreactive T-cell clones were restimu-
lated by the ongmal MLR stimulator in the presence of different doses of esA 
(Table 1). Three clones HA6, AR43 (both DRw6 specific), and AR62 (anri-B 5") 
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TABLE 1 Dose effect of CsA on PLT responsiveness of alloreactive 
T-cell clones 
Percentage innibiclon of PLT response' 
Back- (Cyciosporinc concentration, ng/mI) 
ground PLT:t SD' 
Clone Spec. (cpm) (cpm) (500) (250) (50) m) (5) (0.5) (0.05) 
HA6 DRw6 320 '51.608 :!: 1,887 100 100 97 93 48 26 12 
AR43 DRw6 540 12,')82 :!: 1,245 98 98 96 91 SO 18 a 
AR62 B57 379 37.718 ::!: 2,789 100 100 99 ')8 52 3 4 
AR38 A2 289 9.132 :t 2,126 97 99 70 57 30 0 2 
ARt7 DRw6 480 96.841 ::!: 3,615 100 100 62 47 21 10 10 
DB29 DQwl 450 79.728 ± 7,604 100 97 54 43 22 16 13 
~ The 104 cloned cells were incubated with 10\ irradiated original stimulator cells for 3 days. Results 
represent the mean of triplicate wells. 
, SD is less than 15%. 
showed the highest CsA sensitivity. A conceneration of 25 ng/ml was sufficient to 
induce greater than 90% inhibition. Three clones AR38 (ami-A2), AR17 (anti-
DRw6). and DB29 (anti-DQwl associated) were more resistant (0 the inhibitory 
effects ofCsA: 250 ng/ml was needed to obtain more than 90% inhibition. These 
results show that alloreactive clones have different CsA sensitivity of their sec-
ondary proliferation. 1n this small group ofT-cell clones, no differences in CsA 
sensitivity were shown to correlate with the specificity coward class I and II HLA 
antigens. 
Cyclosporine A Effect on Donor-Specific Secondary Proliferation of 
Allo.reactive Lymphocytes Propagated from Heart Transplant Biopsies 
Nine heart biopsy-grown lymphocyte cuI cures were tested for donor-specific 
proliferative responses in the presence of various concentrations of CsA (Table 
2). These biopsies were originally obtained from different patients at post-trans-
plancintervals ranging from IS to 162 days. Three cultures HB 5,83, HB 12.87, 
and HB 8,48 showed the highest CsA sensitivity. Four cultures required approxi-
mately tenfold higher amounts of CsA to reach the same degree of inhibition. 
HB 9.41 and HB 10.162 showed a considerable resistance to the in vitro im-
munosuppressive effects of CsA. Even at a highest tested concentration of 50 
ng/ml, there was only slightly above 50% inhibition of donor-specific prolifera-
tion. These lymphocytes originated from heart transplant biopsies obtained from 
cwo patients following treatment of an acute rejection episode. It seems possible 
that the increased immunosuppression used to treat the rejection episode had a 
selective effect on grafe-infiltrating lymphocytes, whereby only the more resistant 
cells remained and subsequently could be propagated from the biopsy. 
These observations demonstrate differences in CsA sensitivity of lymphocyte 
cultures propagated from heart transplant biopsies, and these findings are consis-
tent with differences in CsA sensitivity of alloreactive T-cell clones. 
Inhibition of Con A-Induced Proliferation by Bile-Derived Cyclosporine 
A Metabolite Fractions 
The esA and 13 HPLC fractions of bile-derived CsA metabolites were tested for 
their inhibitory effect on Con A-induced proliferation ofPBL (Figure 3). Greater 
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TABLE 2 Cyclosporine A effect on the donor-specific PLT response of 
lymphocyte cultures generated from transplant heart biopsies 
Percenrage inhibition of 
PLT response' 
PLT (Cyclosporine concentration. ng/ml) 
Background Donor:!: sOl 
HB culture' (cpm) (epm) (50) (5) (0.5) (O.Oj) 
5.83 12.992 75,462 ± 3.773 99 99 65 35 
12.87 667 30,431 ± 1.825 99 99 48 20 
8.48 768 12,474 ± 997 97 73 26 18 
10.142 356 11.028 ± 1.016 94 58 36 5 
7.147 350 54.628 ± 4,516 98 58 13 10 
4.39 480 27,504 ± 1.925 90 52 S 2 
6.l5 207 22,498 ± 1,034 93 35 1 0 
9.41 368 7.158 ± 572 58 12 3 0 
10.162 341 34.547 ± 3,145 54 11 0 0 
• Each heart biopsy (BB) culture is referred to by twO numbers. The first number identifies the 
patient and the second number refers to the day post transplant when the biopsy was obtained. 
• Results represent the mean of triplicate wells. 
'SO is less than 15%. 
than 80% inhibition was observed with CsA doses at concentrations of. 5 ILg/ml 
or greater. Several fractions, especially 8, 9, 10, and 13, induced siggificant 
inhibition of Con A-induced proliferation, but higher concentrations were neces-
sary, namely 5 p.g/ml. No effect was noted for any of these fractions at .OS p.g/ml 
or lower. The highest degree of inhibition (about 50%) was observed with frac-
tions 8 and 9, which primarily contained metabolites M17 and MI, respectively. 
Both fractions required about IOO-fold higher concentrations than the .05 ILg/rrJ 
concentration of CsA to induce a 50% inhibition of the Con A response. Other 
fractions including 10 and 13, which contained metabolites MIS and M21, 
FIGURE 3 Inhibition of Con A-induced proliferation by CsA and 13 bile-derived 
metabolites. (Left) Dose effect of CsA and metabolites M17 , M I, and M21. (Right) Effect 
of bile-derived CsA metabolite fractions used at concentration of 5 /LSI ml. Fractions 
corresponding to MI7. Ml, MI8, M21, M13, M9, and M8 are identified. Representative 
results of duplicate experiments. Con A response was 71,624 ± 2.704 cpm. 
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FIGURE 4 Effece of CsA an~ irs metabolites on MLR-induced proliferation. (Left) 
J?ose effect of CsA an~ metabolites MI7, Ml, M21, M13, and fraction 4. (Right) Inhibi-
tion of MLR response 10 the presence of 5 Mgt ml of esA metabolite fractions Rep e 
. I f d l' . M . r senta-tlve resu tS 0 up Icate experlmenrs. LR response was 23,168 ± 1,335 cpm. 
showed even weaker inhibitory effects On Con A-induced proliferation. These 
studies demonstrate rhat HPLC fractions of bile-derived esA metabolites had 
considerably lower inhibirory effects on Con A responsiveness of PBL. 
Mixed Leukocyte Reaction Inhibition by Bile-Derjved 
Cyc1osporine A Metabolites 
The HPLC fractions were studied foe their effect on the primary MLR (Figure 4). 
Greater than 80% MLR inhibition was observed for CsA at doses as low as 0.05 
J.Lg/ml. Signiticanr inhibition was observed with fractions 4, 6, 8, 9, and 13 at 5 
J.l.81ml concenrrations. Especially, fraction 8, which contained M17, exhibited 
comparable inhibitory activity observed with 5 J.Lg/ml of CsA. Even a lower 
concentration of fraction 8 at O. '5 !J.gl ml, there was almost 80% inhibition. On the 
other hand, no significant inhibitory effect was observed for the other fractions at 
concencrations of O. '5 J.l.g/ml. 
These observations demonstrate that several HPLC-fractionated CsA metabo-
lites in bile have significant inhibitory effects on MLR.-induced proliferation. 
Especially fraction 8 (M 17) was strongly inhibitory, almost approaching that of 
CsA itself. This is in contrast to the considerably lower inhibitory effects of CsA 
metabolites on Con A-induced proliferation. 
Fractions ()btruned from concrol bile showed no inhibitory activity on lympho-
eyre proliferation induced by Con A or MLR (data not shown). These results 
indicate thac the HPLC-fraccionated CsA metabolites found in bile are not non-
specifically roxie [() T lymphocytes. 
Cyclosporine A Metabolite Effects on Primed Lymphocyte Test 
Responses of AJloreactive T-Cell Clones 
Two a1lorcacrive T-cell clones HA-6 (anti-DRw6) and DB29 (anti-DQwl associ-
ated) were tested in secondary proliferation assays in the presence of ~ile metab-
olites of CsA rractionared by HPLC (Figures '5 and 6). As may be seen 1? q~~le 1, 
clone HA6 was more sensitive co CsA than clone DB29. The strongest gnhlbl~~ry 
effects were observed with fractions 8, 9. and 13. The differences in CsA. sens~~v~ 
icy between clones HA6 and OB29 were also observed for the me~abolitesK 
concenrration of '5 J.Lg/ml, fraction 13. which contained metabolite M21, was 
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FIGURE 5 Inhibition of PLT reactivity of clone HA6 by CsA metabolite fractions. 
(Left) Dose effect of CsA and metabolites M17, Ml, and M21. (Right) Effect of CsA 
metabolite fractions (5 p.g/ml) on the PLT response. Representative results of triplicate 
experiments. PLT response of HA6 was 12,069 ± 1,301 cpm. 
strongly inhibitory to CsA-sensitive HA6 but not co DB29. Also, the inhibition 
by fraction 9, which contained MI, was higher for HA6 than for DB29. Figure ') 
shows that fraction 8, which contained MI7, had equally high inhibitory effects 
on HA6 and DB29. It may also be seen that several fractions showed weak 
inhibitory effects on HA6 but not DB29. These findings show that similar differ-
ences in CsA sensitivity among alloreactive T-cell clones may also be observed 
for the various CsA metabolites. 
Cyciosporine A Metabolite Effects on Liver Transplant 
Biopsy-Grown Lymphocytes 
The CsA and four bile-derived metabolites (Ml7, MI, MIS, and M21) were 
tested for their inhibitory effect on donor-specific PLT response of alloreactive 
lymphocytes generated from a liver transp!ant biopsy. As shown in Table 3, all 
FIGURE 6 Inhibition ofPLT response of alloreactive clone DB29. (Left) Dose effect uf 
CsA and metabolites M17, MI, and M21. (Right) Inhibition profile ofPLT response in the 
presence of CsA metabolite fractions (5 /-Lgiml). Representative results of triplicate exper-
iments. PLT response of DB29 was 25,377 ::!: 1,376 cpm. 
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TABLE 3 Dose effect of CsA and metabolites MI7 MI MI8 d M2 PLT e f 1 ' ) , an 1 on 
1. rb·sponse a ymphocyte cultures generated from transplant Iver 10pSy 
Drug Percencage inhibition of PLT response' 
concencradon 
(J.Lg/mll esA M17 Ml M18 M21 
S.C 99 99 99 85 99 
0.5 98 94 91 52 69 
0.25 96 84 73 28 SO 
0.05 94 27 25 30 2S 
0.005 40 7 13 40 24 
• The PLT response of liver biopsy alloreactive lymphocytes against donor cells was 20 330 ± 1 568 
cpm. Results represenr mean of duplicate cells. SD is less than 15%. " 
four CsA metabolites tested str??gly inhibite? the PLT reactivity of liver biopsy 
lymp~oc~t:s at 5 gk~/KmlK In addlt1on, metabolites MI7 and MI exhibited compa-
rable Inhibitory activity observed with all doses of parent compound CsA. These 
results indicate t~at bile-derived CsA metabolites have significant inhibitory ef-
fects on alloreacclve T cells derived from cellular infiltrates of liver allograft. 
DISCUSSION 
This study was designed to assess the in vitro immunosuppressive effects of 
various esA metabolites in human bile from liver transplant patients. Besides 
Con A responsiveness and primary MLR activation ofPBL, the assays focused on 
che secondary proliferative responses of cloned alloreactive T cells and transplant 
biopsy-grown lymphocytes. These studies also considered differences between 
activated T cells in their sensitivity to CsA and its metabolites. This seemed 
particularly relevant to allograft infiltrating lymphocytes, which, in the allogeneic 
environment of the graft may undergo further proliferation and subsequently 
cause transplant rejection. The intragraft levels of CsA and its metabolites would 
likely contribute to the outcome of the transplant. 
Secondary proliferation experiments on MLR-generated alloreactive T-cell 
clones showed significant differences in GsA responsiveness among the various 
clones. Certain clones required tenfold larger doses than other more "sensitive" 
clones. These observations are similar to the findings by Manca et al [6], who 
studied MLR-derived T-cell lines. Our data indicate that CsA sensitivity appears 
independent from the specificity of alloreactiveT-cell clones toward class I and II 
HLA antigens. 
Differences in CsA sensitivity were also observed with lymphocyte cult~r~s 
propagated from heart transplant biopsies. These activated T cells often exhibIt 
alJospecificicy toward donor HLA antigens [2,4,13]. Although the presence ~f 
alloreaccive T cells correlated with allograft rejection, on many occaSlOns t.here IS 
little evidence of an ongoing or upcoming rejection episode. The ~atter mt~ht be 
due (0 suppressor cells that inhibit cell-mediate?e~fec[nr me~hantsm: leadln~ to 
rejection. Another possibility that the CsA senS!t1Vlty of graft 1a~ltratlfig cells ~s a 
factor whether or not the allograft undergoes rejection. In thiS study on mae 
biopsy-grown lymphocyte cultures, we observed a lOO-fold range of ~fffere?~es 
in CsA sensitivity. Of particular interest were the twO relatively CsA-lfiSenslt?e 
cultures thar were grown from biopsies after a steroid bolus treatment 0 a 
15:; Zeevi et al. 
rejection episode. Such treatment results in a marked depletion of lymphocytes 
in the cellular infiltrates, and it seems that a subset of esA-insensitive lympho-
cytes was still present after the steroid treatment. More studies are needed to 
establish a correlation between CsA sensitivity and transplant outcome. 
The effectiveness of CsA therapy must consider the immunosuppressive ef-
fects of individual metabolites. The presence of MLC-inhibitory activity in the 
serum of renal transplant recipients when low levels of parent drug were found 
suggested that esA metabolites may contribute to the immunosuppressive activ-
ity {l4]. Freed et al [lO} have demonstrated that MI7, MI, and M21 are the most 
active CsA metabolites as assessed by in vitro inhibition of mitogen responses, 
allogeneic proliferation, and the inhibition of IL-2 production during MLC. OUt 
studies have also showed that bile fractions containing MI7 followed by MI and 
M21 have most significant in vitro immunosuppressive effects. This is particularly 
apparent in Con A and primary MLR stimulation assays, in which CsA was found 
to be about IOO-fold more inhibitory than MI7, the most active metabolite. On 
the other hand, only lO-fold differences between esA and the most active metab-
olites were observed in the inhibition of the secondary proliferation of 
aIloaccivated T cells. This trend was present with alloreactive T-cell clones and 
liver transplant biopsy-propagated cell cultures. Thus, it seems that CsA metabo-
lites may have relatively greater inhibitory effects on alloreactive T cells, includ-
ing those found in cellular infiltrates of allografts, than on the primary activation 
ofT cells. 
The exact contribution of CsA metabolites to the overall immunosuppressive 
activity depends on the relative concentrations of these metabolites in transplant 
patients. It appears that MI7 is a major metabolite of esA and is pres\=nt in 
concentrations greater than that of esA in kidney [9}, liver, and heart transplant 
patients [15}. A comprehensive therapeutic strategy should then include moni-
toring of not only CsA but also the active metabolites. 
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